The HiPRESS study is focused on patients with disseminated cancer, which refers to cancer that has spread from its original site to other parts of the body. The study is investigating a treatment involving a medication called argipressin, also known as arginine vasopressin. This medication is being tested to see if it can reduce the amount of fluid given to patients during a specific type of surgery called cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). This surgery is used to remove as much of the cancer as possible and is followed by heated chemotherapy applied directly inside the abdomen.

The purpose of the study is to determine if using low doses of argipressin can decrease the total amount of fluid needed during the surgery compared to the standard treatment with another medication called noradrenaline. The study will involve patients who are scheduled to undergo CRS-HIPEC surgery. During the study, some patients will receive argipressin, while others will receive a placebo or the standard treatment. The effects of these treatments will be monitored to see if there is a difference in the amount of fluid required during the operation.

Participants in the study will be observed for various outcomes, including the total fluid given during surgery, fluid balance after surgery, and any signs of fluid overload. The study will also look at potential complications, such as abdominal or lung issues, and the overall recovery quality. The length of hospital stay and any serious complications up to 30 days after surgery will also be recorded. The study aims to provide valuable information on whether argipressin can improve the management of fluid levels during this complex cancer surgery.